AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33533652 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT scores
Number of subjects: 1798
Study 32652684 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic radial artery harvest (ERAH)
Number of subjects: 50
Study 32652684 — intervention group
Group type: COMPARATOR
Intervention: Open radial artery harvest (ORAH)
Number of subjects: 50
Study 34433892 — intervention group
Group type: EXPERIMENTAL
Intervention: XGB model
Number of subjects: 2349
Study 34433892 — intervention group
Group type: EXPERIMENTAL
Intervention: DNN model
Number of subjects: 2349
Study 34433892 — intervention group
Group type: EXPERIMENTAL
Intervention: LGBM model
Number of subjects: 2349
Study 34433892 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models
Number of subjects: 2349
Study 32376981 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Disclosure (TD)
Number of subjects: 970
Study 32376981 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Disclosure (TD) without medical follow-up
Number of subjects: 970
Study 32376981 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Disclosure (TD) with medical follow-up
Number of subjects: 970
Study 32376981 — intervention group
Group type: COMPARATOR
Intervention: In-Person Disclosure (IPD)
Number of subjects: 970
Study 35985896 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group (mHealth technology-assisted vocal training with real-time feedback on pitch, loudness, and duration)
Number of subjects: 23
Study 35985896 — intervention group
Group type: COMPARATOR
Intervention: Control group (mHealth technology-assisted vocal training without real-time feedback)
Number of subjects: 23
Study 32162438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional 2% zinc sulfate
Number of subjects: 105
Study 32162438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional 2% vitamin D3
Number of subjects: 105
Study 32162438 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 105
Study 35918657 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of vancomycin
Number of subjects: 0
Study 35918657 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion (II) of vancomycin
Number of subjects: 0
Study 35442543 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopalm cream® (twice-daily application for three consecutive years)
Number of subjects: 200
Study 35442543 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 200
Study 33840310 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a news literacy video
Number of subjects: 0
Study 33840310 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time user corrections to misinformation video
Number of subjects: 0
Study 33840310 — intervention group
Group type: COMPARATOR
Intervention: Promotional video
Number of subjects: 0
Study 34018670 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized postoperative feeding protocol
Number of subjects: 81
Study 32967742 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of oral powder-based chocolate-flavoured CGMP for 4 weeks
Number of subjects: 24
Study 32967742 — intervention group
Group type: COMPARATOR
Intervention: Reference drink
Number of subjects: 24
Study 32896172 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication guide used by oncologists in the intervention group
Number of subjects: 0
Study 32896172 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication guide
Number of subjects: 0
Study 32896172 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33012641 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% dose reduction of IAsp (2.6 ± 1.2 IU) before and after exercise
Number of subjects: 16
Study 33012641 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% dose reduction of IAsp post-exercise
Number of subjects: 16
Study 33012641 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 50% dose reduction of IAsp before and after exercise
Number of subjects: 16
Study 33012641 — intervention group
Group type: COMPARATOR
Intervention: Regular dose of IAsp (100%; 5.1 ± 2.4 IU)
Number of subjects: 16
Study 33830440 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 3350 (0.7–1.5 mg/kg/day)
Number of subjects: 100
Study 33830440 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (0.7–2.0 g/kg/day)
Number of subjects: 100
Study 33830440 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 3350
Number of subjects: 100
Study 33830440 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 100
Study 34596965 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic debridement (35 patients)
Number of subjects: 78
Study 34596965 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic repair (43 patients)
Number of subjects: 78
Study 34596965 — intervention group
Group type: COMPARATOR
Intervention: Both groups (debridement and repair)
Number of subjects: 78
Study 32388622 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (40 IU intranasal)
Number of subjects: 112
Study 32388622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 32388622 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 112
Study 32388622 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher endogenous progesterone
Number of subjects: 112
Study 35292378 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS (n = 101)
Number of subjects: 301
Study 35292378 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS (n = 99)
Number of subjects: 301
Study 35292378 — intervention group
Group type: COMPARATOR
Intervention: No TENS (n = 99)
Number of subjects: 301
Study 35292378 — intervention group
Group type: EXPERIMENTAL
Intervention: RTO group
Number of subjects: 301
Study 33208855 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) treatment for menopausal hot flushes, twice a day for four weeks
Number of subjects: 100
Study 34412521 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg/d (n = 43)
Number of subjects: 84
Study 34412521 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 41)
Number of subjects: 84
Study 35040974 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer convalescent plasma
Number of subjects: 0
Study 34134736 — intervention group
Group type: COMPARATOR
Intervention: Hearing for Learning Initiative (HfLI) - six 20-hour weeks of training over 3 months, including Certificate II in Aboriginal Primary Health Care and competencies in ear and hearing data collection, followed by part-time employment as Ear Health Facilitators.
Number of subjects: 18
Study 34134736 — intervention group
Group type: COMPARATOR
Intervention: Hearing for Learning Initiative (HfLI)
Number of subjects: 18
Study 35513301 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g cephazolin
Number of subjects: 117
Study 35513301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10-mL normal saline)
Number of subjects: 117
Study 34496013 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab
Number of subjects: 1362
Study 34496013 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1362
Study 35869554 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Xiao-Feng Powder (mXFP) with antihistamine Bilastine
Number of subjects: 58
Study 35869554 — intervention group
Group type: COMPARATOR
Intervention: placebo with antihistamine Bilastine
Number of subjects: 58
Study 32604135 — intervention group
Group type: EXPERIMENTAL
Intervention: HEROS program
Number of subjects: 1929
Study 32604135 — intervention group
Group type: COMPARATOR
Intervention: non-HEROS program
Number of subjects: 1929
Study 34000661 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected Lynch syndrome-associated endometrial cancer
Number of subjects: 377
Study 34000661 — intervention group
Group type: COMPARATOR
Intervention: Sporadic endometrial cancer
Number of subjects: 377
Study 34000661 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES)
Number of subjects: 377
Study 32891418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin/Fenofibrate combination therapy (2/160 mg)
Number of subjects: 347
Study 32891418 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin monotherapy (2 mg)
Number of subjects: 347
Study 33024002 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory positive airway pressure
Number of subjects: 10
Study 33024002 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-stacking maneuver
Number of subjects: 10
Study 33024002 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study 32303867 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy-to-hard training schedule
Number of subjects: 6
Study 32303867 — intervention group
Group type: COMPARATOR
Intervention: Constant-hard training schedule
Number of subjects: 6
Study 32303867 — intervention group
Group type: EXPERIMENTAL
Intervention: First trial performance
Number of subjects: 6
Study 35156503 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational-educational songwriting (MESW)
Number of subjects: 134
Study 35156503 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational music therapy (RMT)
Number of subjects: 134
Study 35156503 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 134
Study 32723201 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (414 lux)
Number of subjects: 49
Study 32723201 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light (201 lux)
Number of subjects: 49
Study 32723201 — intervention group
Group type: COMPARATOR
Intervention: Dim darkened light (<2 lux)
Number of subjects: 49
Study 32723201 — intervention group
Group type: COMPARATOR
Intervention: Red light (235 lux)
Number of subjects: 49
Study 33153482 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care psychosocial intervention (17-week program delivered at home by community health workers with tablet application)
Number of subjects: 1440
Study 33153482 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control arm)
Number of subjects: 1440
Study 33153482 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care psychosocial intervention
Number of subjects: 1440
Study 34585598 — intervention group
Group type: EXPERIMENTAL
Intervention: del Nido cardioplegia (DN)
Number of subjects: 110
Study 34585598 — intervention group
Group type: COMPARATOR
Intervention: cold blood cardioplegia (CB)
Number of subjects: 110
Study 34852731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 28
Study 34852731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-water immersion (HWI)
Number of subjects: 28
Study 34852731 — intervention group
Group type: COMPARATOR
Intervention: Passive resting
Number of subjects: 28
Study 32492293 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days)
Number of subjects: 821
Study 32492293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study 32492293 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 821
Study 34240198 — intervention group
Group type: EXPERIMENTAL
Intervention: Veverimer
Number of subjects: 196
Study 34240198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 33792007 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-strand locking multi-level repair
Number of subjects: 38
Study 33792007 — intervention group
Group type: COMPARATOR
Intervention: Four-strand locking multi-level repair
Number of subjects: 38
Study 33792007 — intervention group
Group type: COMPARATOR
Intervention: Two-strand locking multi-level repair
Number of subjects: 38
Study 32877975 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA
Number of subjects: 26
Study 34563715 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum Drains (VD)
Number of subjects: 78
Study 34563715 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Drains (PD)
Number of subjects: 78
Study 34563715 — intervention group
Group type: COMPARATOR
Intervention: No Drains (ND)
Number of subjects: 78
Study 35392739 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (240 mg loading dose, then 120 mg/month thereafter)
Number of subjects: 1022
Study 32681228 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics/Hydroxychloroquine (ciprofloxacin 500 mg bd, doxycycline 100 mg bd, hydroxychloroquine 200 mg tds for 4 weeks, followed by doxycycline 100 mg bd and hydroxychloroquine 200 mg tds for 20 weeks)
Number of subjects: 59
Study 32681228 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (Entocort CR 9 mg/day for 8 weeks, 6 mg/day for 2 weeks, 3 mg/day for 2 weeks)
Number of subjects: 59
Study 32681228 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics/Hydroxychloroquine (including crossover)
Number of subjects: 59
Study 32681228 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (including crossover)
Number of subjects: 59
Study 32590001 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed lipid emulsion containing fish oil
Number of subjects: 230
Study 32590001 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil-based lipid emulsion
Number of subjects: 230
Study 36045256 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mobile training and consultancy services (mobile application) for 3 months post-operation
Number of subjects: 51
Study 36045256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no e-mobile training and consultancy services)
Number of subjects: 51
Study 33349506 — intervention group
Group type: EXPERIMENTAL
Intervention: Low functional health literacy (inadequate or marginal S-TOFHLA scores)
Number of subjects: 1066
Study 33349506 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, male sex, lower reading level
Number of subjects: 1066
Study 33349506 — intervention group
Group type: COMPARATOR
Intervention: Higher S-TOFHLA scores
Number of subjects: 1066
Study 35014600 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic formula (strains Lactiplantibacillus plantarum KABP022, KABP023, KAPB033, plus strain Pediococcus acidilactici KABP021, totaling 2 × 10^9 CFU)
Number of subjects: 300
Study 35014600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 35014600 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic formula
Number of subjects: 300
Study 32877236 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 18
Study 32877236 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 18
Study 36125835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) for 10 consecutive working days
Number of subjects: 28
Study 36125835 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 28
Study 32472292 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine 3000 mg/daily for 8 weeks
Number of subjects: 45
Study 32472292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (crystalline microcellulose/daily for 8 weeks)
Number of subjects: 45
Study 35545412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.3 μg/(kg·h) (Dex1 group)
Number of subjects: 120
Study 35545412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 μg/(kg·h) (Dex2 group)
Number of subjects: 120
Study 35545412 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 120
Study 35545412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex1 and Dex2 groups)
Number of subjects: 120
Study 35545412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex2 group)
Number of subjects: 120
Study 33217839 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion therapy (3 times a week for 3 menstrual cycles)
Number of subjects: 246
Study 33217839 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion therapy
Number of subjects: 246
Study 33217839 — intervention group
Group type: COMPARATOR
Intervention: IVF-ET only
Number of subjects: 246
Study 35501072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex group
Number of subjects: 162
Study 35501072 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 162
Study 36221399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral endoscopic drainage with self-expanding metallic stents (SEMS)
Number of subjects: 0
Study 36221399 — intervention group
Group type: COMPARATOR
Intervention: Trisegmental endoscopic drainage using self-expanding metallic stents (SEMS)
Number of subjects: 0
Study 32574587 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dupilumab every 4 weeks + medium-potency topical corticosteroids (TCS)
Number of subjects: 367
Study 32574587 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based regimen of dupilumab every 2 weeks + medium-potency TCS
Number of subjects: 367
Study 32574587 — intervention group
Group type: COMPARATOR
Intervention: Placebo + medium-potency TCS
Number of subjects: 367
Study 35132952 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Control Training (ACT)
Number of subjects: 60
Study 35132952 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 60
Study 35132952 — intervention group
Group type: COMPARATOR
Intervention: Control Group (ACT)
Number of subjects: 60
Study 34193491 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred counselling and external adherence support for ART
Number of subjects: 300
Study 34193491 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred counselling and external adherence support for PrEP
Number of subjects: 300
Study 34193491 — intervention group
Group type: COMPARATOR
Intervention: Standard counselling based on local HIV guidelines
Number of subjects: 300
Study 32230954 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine (6 g/day)
Number of subjects: 50
Study 32230954 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose, 6 g/day)
Number of subjects: 50
Study 34666412 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsiate (12 mg)
Number of subjects: 13
Study 34666412 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch: 12 mg)
Number of subjects: 13
Study 32036372 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive participants (1,349 out of 12,125, 11.1% of total population)
Number of subjects: 12125
Study 32036372 — intervention group
Group type: COMPARATOR
Intervention: Normal weight participants
Number of subjects: 12125
Study 32036372 — intervention group
Group type: COMPARATOR
Intervention: Overweight participants
Number of subjects: 12125
Study 32036372 — intervention group
Group type: COMPARATOR
Intervention: Obese participants
Number of subjects: 12125
Study 32036372 — intervention group
Group type: COMPARATOR
Intervention: All subjects
Number of subjects: 12125
Study 32036372 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive participants
Number of subjects: 12125
Study 33932162 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (6 mg) administered to cannabis users (CU)
Number of subjects: 43
Study 33932162 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered to cannabis users (CU)
Number of subjects: 43
Study 33932162 — intervention group
Group type: COMPARATOR
Intervention: Non-cannabis users (NU)
Number of subjects: 43
Study 33516285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor therapy
Number of subjects: 239
Study 33516285 — intervention group
Group type: COMPARATOR
Intervention: Placebo to treatment group
Number of subjects: 239
Study 32766331 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program based on social cognitive theory (SCT)
Number of subjects: 70
Study 32766331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 34371137 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance from caregivers
Number of subjects: 541
Study 34371137 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance from research staff
Number of subjects: 541
Study 34371137 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance from both caregivers and research staff
Number of subjects: 541
Study 34371137 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assistance in completing PROs
Number of subjects: 541
Study 34688297 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Cancer Screening Decision Tool (LCSDecTool)
Number of subjects: 0
Study 34688297 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study 32907824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 18040
Study 32907824 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 18040
Study 32043288 — intervention group
Group type: COMPARATOR
Intervention: saxagliptin (5 mg/day) plus conventional therapy
Number of subjects: 60
Study 32043288 — intervention group
Group type: EXPERIMENTAL
Intervention: vitamin D3 (2000 IU/day) plus saxagliptin and conventional therapy
Number of subjects: 60
Study 32043288 — intervention group
Group type: COMPARATOR
Intervention: conventional therapy with metformin (1-1.7 g/day) and/or insulin treatment
Number of subjects: 60
Study 34293826 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sclerosis (MS) patients
Number of subjects: 5548
Study 34293826 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sclerosis (MS) patients with comorbidities
Number of subjects: 5548
Study 34293826 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 5548
Study 33464732 — intervention group
Group type: EXPERIMENTAL
Intervention: Thetanix (Bacteroides thetaiotaomicron)
Number of subjects: 15
Study 35001410 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training + placebo (CT)
Number of subjects: 60
Study 35001410 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron supplementation (S)
Number of subjects: 60
Study 35001410 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training + saffron supplementation (CTS)
Number of subjects: 60
Study 35001410 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 60